The Orbital Booster turns the centrifuge already in your lab into an intracellular delivery system.
Orbital boosters enable novel cell engineering and drug discovery in a single spin.
No new instruments
Orbital runs in the centrifuge you already have, no new instruments or integrations needed.
Any cell, any cargo
Each booster is validated for a specific cell type, and works with any cargo: DELs, RNPs, mRNA, proteins, etc.
Ready-to-run
Each booster is designed for a specific cell type, and ships with ready-to-run protocol so you can skip the optimization.
Cost effective
Test a new idea for the cost of a booster, not an instrument.
No new instruments
Orbital runs in the centrifuge you already have, no new instruments or integrations needed.
Any cell, any cargo
Each booster is validated for a specific cell type, and works with any cargo: DELs, RNPs, mRNA, proteins, etc.
Ready-to-run
Each booster is designed for a specific cell type, and ships with ready-to-run protocol so you can skip the optimization.
Cost effective
Test a new idea for the cost of a booster, not an instrument.
As the booster spins, cells squeeze through tiny pores and take in cargo while preserving cell health and function.
Load your cells and cargo along with your validated, cell-type specific booster.
Run your centrifuge at the speed and time in the booster protocol.
Collect your boosted cells, with health and function intact, and jump straight into your assay!
The Orbital technology enables highly efficient delivery of impermeable cargos into cells, achieving 70-90% delivery across both primary human cells and immortalized cell lines.
Portal’s Orbital platform is compatible with a variety of cell types, preserving ~80% viability post-delivery.
The Orbital platform supports easy cargo multiplexing and enables functional expression of nucleic acids upon intracellular delivery. Co-delivery with fluorescently labeled IgG antibody and dextran resulted in 79% double-positive HeLa cells immediately post-delivery (left), while co-delivery of labeled dextran with circular RNA encoding GFP showed 74% positive expression in HeLa cells 24 hours post-delivery (right).
Research Scale
High-Throughput Screening
Clinical Manufacturing
Validated Workflows
